PPD Akcija

PPD EBITDA

Delisted·9. дец 2021.

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od PPD (PPD) na dan 12. авг 2026. je 788,53 М USD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio 635,82 М USD — promjena od 24,02% (viši).

EBITDA

788,53 МUSD

YoY

24,02%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od PPD je 2026 788,53 М USD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od PPD je bio 2025 635,82 М USD. Pad je time 24,02% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

PPD Анализа акција

Šta radi PPD? PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs. PPD je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji PPD

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije PPD iznosi 788,53 М USD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od PPD se promijenio sa 635,82 М USD na 788,53 М USD, što predstavlja promjenu od 24,02%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) PPD od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s USD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s PPD istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — PPD

Sve ključne metrike — PPD

Раст